Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
To prevent progression of sex hormone-responsive prostate and breast tumours, anti-androgens and anti-oestrogens are commonly used to induce androgen and oestrogen withdrawal. Zoladex is a potent luteinising hormone-releasing hormone agonist analogue, which has a selective effect on pituitary gonadotrophin release, and is highly effective at inducing regression of sex hormone-responsive prostate and breast tumours. Its depot formulation, active for at least 28 days, is convenient to administer and well tolerated and for the treatment of sex hormone-responsive tumours in men and women, Zoladex is an effective alternative to surgery.
Furr
B J
BJ
Bioscience I, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.
D000818:Animals; D002064:Buserelin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D017273:Goserelin; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats
D017273:Goserelin; D002064:Buserelin